Loading…
Develops RNA-based medicines that restore normal levels of proteins missing in genetic diseases like Dravet syndrome.
Develops RNA-based medicines that restore normal levels of proteins missing in genetic diseases like Dravet syndrome.
Has no medicine on the market, so it lives on cash from shareholders and partner payments, and nearly all its value rests on one lead medicine for Dravet syndrome. The approach raises output from the healthy copy of the affected gene, and Biogen is a partner on its central-nervous-system work.
Moat: narrow (IP / patents, process know-how). Proprietary TANGO antisense oligonucleotide technology targets gene splicing to restore protein levels.
Headquarters: Bedford, Massachusetts, US · Founded: 2014 · Employees: 170
Size Stoke Therapeutics (STOK) is a United States Health Care company (Biotechnology) with a market value of $1.74B, the 1889th largest of 3,117 United States companies the cockpit tracks. Shares closed at $26.54 on 6 Nov 2026.
Performance Over six months the shares fell 19.3%, against +2.4% for the median peer and -1.1% for the United States market (cap-weighted) — 6th lowest of 19 in its peer set.
Growth Revenue fell 86.3% over the last twelve months (peer median +20.2%); the operating margin is -913.1% (peer median -43.2%).
Valuation It trades at 50.3× enterprise value to sales against a peer median of 15.0× (6th most expensive of 19).
Short interest Short interest is 15.9% of the free float (15 Oct 2026).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $28.2M | $184M | $36.6M | $8.78M | $12.4M |
| Revenue growth | — | +405% | +316% | -29% | — |
| Gross profit | $23.9M | $180M | $32.1M | $4.05M | $8.87M |
| EBITDA | -$253M | -$16.4M | -$96.9M | -$110M | -$101M |
| Net income | -$243M | -$6.88M | -$89.0M | -$105M | -$101M |
| Free cash flow | -$216M | $44.9M | -$87.1M | -$82.7M | -$35.8M |
| Capital expenditure | $5.41M | $670,000 | $203,000 | $1.62M | $3.96M |
| Total debt | $1.92M | $4.15M | $4.77M | $6.83M | $5.08M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Stoke Therapeutics STOK | $1.74B | -19% | -86% | -913% | 50.3× | n/a |
| Ionis Pharmaceuticals IONS | $6.55B | -48% | -7% | -68% | 7.7× | n/a |
| Biogen BIIB | $36.7B | +28% | +2% | 17% | 4.4× | 9.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STOK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.8% | -9.9% | 3rd highest of 20 |
| 6-month return | -19.3% | +2.4% | 6th lowest of 19 |
| Distance from 52-week high | -34.0% | -38.6% | 8th highest of 20 |
| Revenue growth (TTM) | -86.3% | +20.2% | 2nd lowest of 20 |
| Operating margin | -913.1% | -43.2% | 4th lowest of 20 |
| EV / Sales | 50.3× | 15.0× | 6th most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.73B | +21% | +30% | -4% | 8.5× | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 4.5× | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | 3.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | 15.2× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.84B | +44% | -93% | -27,390% | 1,588.4× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Alvotech ALVO | United States | $1.90B | +49% | -12% | 9% | 6.5× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |